These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 27466467)

  • 1. Anti-LGI1-associated cognitive impairment: Presentation and long-term outcome.
    Ariño H; Armangué T; Petit-Pedrol M; Sabater L; Martinez-Hernandez E; Hara M; Lancaster E; Saiz A; Dalmau J; Graus F
    Neurology; 2016 Aug; 87(8):759-65. PubMed ID: 27466467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three cases of antibody-LGI1 limbic encephalitis and review of literature.
    Bing-Lei W; Jia-Hua Z; Yan L; Zan Y; Xin B; Jian-Hua S; Hui-Juan W
    Int J Neurosci; 2019 Jul; 129(7):642-648. PubMed ID: 30112956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of limbic encephalitis with VGKC-complex antibodies: relation to antigenic specificity.
    Malter MP; Frisch C; Schoene-Bake JC; Helmstaedter C; Wandinger KP; Stoecker W; Urbach H; Surges R; Elger CE; Vincent AV; Bien CG
    J Neurol; 2014 Sep; 261(9):1695-705. PubMed ID: 24935858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and Prognostic Value of Immunogenetic Characteristics in Anti-LGI1 Encephalitis.
    Muñiz-Castrillo S; Haesebaert J; Thomas L; Vogrig A; Pinto AL; Picard G; Blanc C; Do LD; Joubert B; Berzero G; Psimaras D; Alentorn A; Rogemond V; Dubois V; Ambati A; Tamouza R; Mignot E; Honnorat J
    Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33848259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural course of LGI1 encephalitis: 3-5 years of follow-up without immunotherapy.
    Szots M; Marton A; Kover F; Kiss T; Berki T; Nagy F; Illes Z
    J Neurol Sci; 2014 Aug; 343(1-2):198-202. PubMed ID: 24928080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-LGI1 encephalitis: Clinical syndrome and long-term follow-up.
    van Sonderen A; Thijs RD; Coenders EC; Jiskoot LC; Sanchez E; de Bruijn MA; van Coevorden-Hameete MH; Wirtz PW; Schreurs MW; Sillevis Smitt PA; Titulaer MJ
    Neurology; 2016 Oct; 87(14):1449-1456. PubMed ID: 27590293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical features, investigations, and outcomes of pediatric limbic encephalitis: A multicenter study.
    Sabanathan S; Abdel-Mannan O; Mankad K; Siddiqui A; Das K; Carr L; Eltze C; Eyre M; Gadian J; Hemingway C; Kaliakatsos M; Kneen R; Krishnakumar D; Lynch B; Parida A; Rossor T; Taylor M; Wassmer E; Wright S; Lim M; Hacohen Y
    Ann Clin Transl Neurol; 2022 Jan; 9(1):67-78. PubMed ID: 35015932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical characteristics and short-term prognosis of LGI1 antibody encephalitis: a retrospective case study.
    Li W; Wu S; Meng Q; Zhang X; Guo Y; Cong L; Cong S; Zheng D
    BMC Neurol; 2018 Jul; 18(1):96. PubMed ID: 29980179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VGKC-complex/LGI1-antibody encephalitis: clinical manifestations and response to immunotherapy.
    Shin YW; Lee ST; Shin JW; Moon J; Lim JA; Byun JI; Kim TJ; Lee KJ; Kim YS; Park KI; Jung KH; Lee SK; Chu K
    J Neuroimmunol; 2013 Dec; 265(1-2):75-81. PubMed ID: 24176648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LGI1 antibody encephalitis: acute treatment comparisons and outcome.
    Rodriguez A; Klein CJ; Sechi E; Alden E; Basso MR; Pudumjee S; Pittock SJ; McKeon A; Britton JW; Lopez-Chiriboga AS; Zekeridou A; Zalewski NL; Boeve BF; Day GS; Gadoth A; Burkholder D; Toledano M; Dubey D; Flanagan EP
    J Neurol Neurosurg Psychiatry; 2022 Mar; 93(3):309-315. PubMed ID: 34824144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Patient with Limbic Encephalitis Associated with Anti-leucine-rich Glioma-inactivated 1 (LGI1) Antibody Presenting with Slowly Progressive Cognitive Impairment and Fluctuating Striatal Lesions.
    Sato M; Kishida D; Miyazaki D; Sekijima Y
    Intern Med; 2019 Jan; 58(2):287-291. PubMed ID: 30146575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Treatment and Follow-Up of Anti-LGI1 Limbic Encephalitis.
    Yu J; Yu X; Fang S; Zhang Y; Lin W
    Eur Neurol; 2016; 75(1-2):5-11. PubMed ID: 26694143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Limbic encephalitis with LGI1 antibodies in a 14-year-old boy.
    Schimmel M; Frühwald MC; Bien CG
    Eur J Paediatr Neurol; 2018 Jan; 22(1):190-193. PubMed ID: 28919330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LGI1 antibody-associated encephalitis without evidence of inflammation in CSF and brain MRI.
    Jia Y; Wang H; Zhang M; Wei M; Huang Z; Ye J; Liu A; Wang Y
    Acta Neurol Belg; 2023 Jun; 123(3):849-856. PubMed ID: 35527332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis.
    Vincent A; Buckley C; Schott JM; Baker I; Dewar BK; Detert N; Clover L; Parkinson A; Bien CG; Omer S; Lang B; Rossor MN; Palace J
    Brain; 2004 Mar; 127(Pt 3):701-12. PubMed ID: 14960497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LGI1 encephalitis: potentially complement-activating anti-LGI1-IgG subclasses 1/2/3 are associated with the development of hippocampal sclerosis.
    Bien CG; Rada A; Mertens M; Bien CI; Bauer J; Hagemann A; Woermann FG
    J Neurol; 2024 Sep; 271(9):6325-6335. PubMed ID: 39105896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Features, Immunotherapy, and Outcomes of Anti-Leucine-Rich Glioma-Inactivated-1 Encephalitis.
    Huang X; Fan C; Gao L; Li L; Ye J; Shen H
    J Neuropsychiatry Clin Neurosci; 2022; 34(2):141-148. PubMed ID: 34794327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical features of nine cases of leucine-rich glioma inactivated 1 protein antibody-associated encephalitis.
    Li Y; Song F; Liu W; Wang Y
    Acta Neurol Belg; 2021 Aug; 121(4):889-897. PubMed ID: 32232701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The importance of early immunotherapy in patients with faciobrachial dystonic seizures.
    Thompson J; Bi M; Murchison AG; Makuch M; Bien CG; Chu K; Farooque P; Gelfand JM; Geschwind MD; Hirsch LJ; Somerville E; Lang B; Vincent A; Leite MI; Waters P; Irani SR;
    Brain; 2018 Feb; 141(2):348-356. PubMed ID: 29272336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Origin and significance of leucine-rich glioma-inactivated 1 antibodies in cerebrospinal fluid.
    Zhang F; Zhou H; Yi Y; Li N; Liu M; Shen H; Guo Y; Wang J
    Neurol Sci; 2024 Sep; 45(9):4493-4500. PubMed ID: 38551680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.